About Aria Pharmaceuticals
Aria Pharmaceuticals was a Healthcare company based in Palo Alto (United States) founded in 2015 by Andrew Radin. It develops innovative drug technologies for multiple diseases. It operates on a B2B model. Aria Pharmaceuticals has raised $14.31 million across 3 funding rounds from investors including Andreessen Horowitz, OS Fund and SBVA. The company is recorded as dissolved. Its focus areas include Pharmaceuticals, Drug Development and Innovative Technologies. Its legal entity is TWOXAR, INC. Its competitors include Moderna, Forge Biologics and Annexon; 3 of its 3 listed competitors have raised funding.
Company details
Aria Pharmaceuticals operates with a B2B model, focusing on providing healthcare solutions, producing pharmaceutical products, drug development, and innovative technologies. Develops innovative drug technologies for multiple diseases. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
- Headquarters Palo Alto, United States
- Founders Andrew Radin
- SectorsHealthcare
- Website ariapharmaceuticals.com
- Social X Facebook
- Legal Name Twoxar, Inc.
- Total Equity Funding$14.31M (USD)
in 3 rounds
- Latest Funding Round$1.14M (USD), Post-IPO
Jul 2019
- InvestorsAndreessen Horowitz
& 4 more
Funding Insights of Aria Pharmaceuticals
Aria Pharmaceuticals has successfully raised a total of $14.31M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.14 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.31M
- Total Rounds 3
- Last Round Post-IPO — $1.14M
- First Round $4.31M
(Nov 2015)
- Investors Count 5
All 3 funding rounds of Aria Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2019 | $1.14M | Post-IPO | – | – | – |
| Mar 2018 | $10M | Series A | – | – | |
| Nov 2015 | $4.31M | Seed | – | a16z |
5 investors in total: 5 institutional.
Investors in Aria Pharmaceuticals
Aria Pharmaceuticals has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Andreessen Horowitz, OS Fund and SBVA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | a16z.com | |||
Early-stage centric sector-agnostic VC firm investing in geographies such as the US | osfund.co | Chicago, United States | ||
Early-stage venture capital arm of SoftBank Group | sbvacorp.com | Seoul, South Korea | ||
VC Firm investing in geographies such as the US | cli.ventures | Palo Alto, United States | ||
Startups are accelerated by Stanford-backed program in Palo Alto. | startx.com | Palo Alto, United States |
Investor details for Aria Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aria Pharmaceuticals
13 people are tracked at Aria Pharmaceuticals (3 in leadership, 9 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Andrew Radin | ex-Co-Founder | Leadership |
Isaac Hakim | Director of Pre Clinical Studies | Leadership |
Yunsheng (Tony) Hsieh | DMPK Head | Leadership |
Jorge Conde | Director | Board & advisors |
Howard Rosen | Director | Board & advisors |
Nigam Shah | Advisor | Board & advisors |
Judy Lewent | Advisor | Board & advisors |
Scott Stern | Advisor | Board & advisors |
Andrew M. Radin | Advisor | Board & advisors |
Jonathan MacQuitty | Advisor | Board & advisors |
Sherman Li | Director | Board & advisors |
Vijay Pande | Advisor | Board & advisors |
Anjali Pandey | SVP of Non-Clinical R&D & Chemistry | Team |
Complete people profiles for Aria Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Aria Pharmaceuticals
3 dated milestones of Aria Pharmaceuticals across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Aria Pharmaceuticals is founded.
- Funding First funding round of $4.3M.
- Funding Latest funding round, Post-IPO, of $1.1M.
Competitors of Aria Pharmaceuticals
Aria Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Moderna, Forge Biologics and Annexon.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases |
Detailed competitors of Aria Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Clinical Trials & Research Tech
3 companies that operate in the same segment as Aria Pharmaceuticals (Clinical Trials & Research Tech) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Genetic services are provided by Colossal's laboratory operations. | 2021 | Austin, Texas, United States | USD 619.8 M | 252 | ||
Research lab engaged in pharmacological measurements on therapeutic protein variants | 2018 | United States | USD 78.19 M | 22 | ||
Medical research labs are provided by GALY for scientific purposes. | 2018 | Boston, Massachusetts, United States | USD 61.59 M | 25 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aria Pharmaceuticals
Complete news archive for Aria Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aria Pharmaceuticals
Aria Pharmaceuticals was founded in 2015.
Aria Pharmaceuticals is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Aria Pharmaceuticals is a funded company, having raised a total of $14.31M across 3 funding rounds to date. The company's 1st funding round was a Seed of $4.31M, raised on Nov 2015.
Aria Pharmaceuticals operates with a B2B model, focusing on providing healthcare solutions, producing pharmaceutical products, drug development, and innovative technologies. Develops innovative drug technologies for multiple diseases. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
Aria Pharmaceuticals's top competitors include Moderna, Forge Biologics and Annexon.
Aria Pharmaceuticals has 5 investors. Key investors include Andreessen Horowitz, OS Fund, SBVA, CLI Ventures, and StartX.
Aria Pharmaceuticals operates through Twoxar, Inc..